Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 1
2005 2
2006 1
2007 3
2008 2
2009 1
2010 2
2011 1
2012 3
2013 2
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. Schilder RJ, et al. Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13. Gynecol Oncol. 2013. PMID: 23321064 Free PMC article. Clinical Trial.
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Abkevich V, et al. Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9. Br J Cancer. 2012. PMID: 23047548 Free PMC article.
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB. Fu S, et al. Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6. Gynecol Oncol. 2012. PMID: 22487539 Free PMC article. Clinical Trial.
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.
Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC Jr, Hung MC. Xie X, et al. Mol Cancer Ther. 2009 Aug;8(8):2375-82. doi: 10.1158/1535-7163.MCT-09-0056. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671744 Free PMC article.
20 results